文献速递银屑病与炎症性皮肤病

伊克珠单抗在真实世界斑块状银屑病患者中的疗效与安全性初步结果:一项多中心回顾性研究

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-11-13

该多中心回顾性研究纳入7家西班牙皮肤科中心的100例中重度斑块状银屑病患者,评估伊克珠单抗的真实世界疗效与安全性。按实际观察分析,第12-16周PASI 75和PASI 90应答率分别为87.5%和50.0%,第52周分别为82.9%和58.5%;26%患者出现不良事件,多为轻中度。

要点

  • 第12-16周PASI 75和PASI 90应答率分别为87.5%和50.0%,第52周分别为82.9%和58.5%。
  • 生物制剂初治组第12-16周PASI 75应答率显著高于既往生物制剂暴露组(P=0.037)。
  • 26%患者出现不良事件,最常见为注射部位局部反应(14/26;53.8%)。

核心结论

  • 本研究展示了伊克珠单抗在真实世界临床实践中的初步经验,证实其在斑块状银屑病管理中的有效性和安全性。

研究设计与样本

  • 多中心回顾性病历审查,纳入7家西班牙皮肤科中心的100例接受伊克珠单抗治疗的中重度斑块状银屑病患者。

主要发现

  • 按实际观察分析,第12-16周实现PASI 75和PASI 90的患者比例分别为87.5%和50.0%,第24周分别为88.3%和58.4%,第52周分别为82.9%和58.5%。
  • 基线PASI平均±标准差评分为12.9±9.2,第12-16周降至1.9±4.0(P<0.001),第24周和第52周分别维持在1.7±4.1和1.8±2.9。
  • 伊克珠单抗应答不受体重指数、病程或银屑病关节炎存在等临床变量影响。
  • 生物制剂初治组第12-16周PASI 75应答率显著高于既往生物制剂暴露组(P=0.037)。
  • 26例(26%)患者在随访期间出现不良事件,多为轻中度;最常见为注射部位局部反应(14/26;53.8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ixekizumab (anti-IL17A) is effective as treatment for moderate-to-severe plaque psoriasis, but real-life data on effectiveness and safety are currently very limited. OBJECTIVE: To evaluate the efficacy and safety of ixekizumab in a cohort of real-life plaque psoriasis patients. METHODS: Retrospective chart review of 100 patients with moderate-to-severe plaque psoriasis treated with ixekizumab at seven Spanish dermatological centres. RESULTS: According to the as observed analysis, the percentage of patients achieving a 75% and 90% of reduction from the baseline score of Psoriasis Area and Severity Index (PASI) was 87.5%-50.0% at week 12-16; 88.3%-58.4% at week 24 and 82.9%-58.5% at week 52, respectively. The mean ± standard deviation (SD) score of PASI at baseline was 12.9 ± 9.2, and it declined rapidly after ixekizumab administration to 1.9 ± 4.0 (P < 0.001) at week 12-16 and was maintained at 1.7 ± 4.1 and 1.8 ± 2.9 at week 24 and 52, respectively. Ixekizumab response was not affected by clinical variables like body mass index, disease duration or the presence of psoriatic arthritis. However, the bio-naive group showed significantly higher PASI 75 response rate at week 12-16 compared to patients previously exposed to biologic agents (P = 0.037). Twenty-six (26%) patients experienced adverse events (AEs) during the follow-up period, being most of them of mild-to-moderate intensity. The most common AE was local reaction at the site of injection (14/26; 53.8%). At the end of the observational period, 15 (15%) patients discontinued ixekizumab treatment due to limited clinical improvement (n = 11), adverse events (n = 3) or lost to follow-up (n = 1) within a mean ± SD time of 6.0 ± 3.9 months. CONCLUSION: The present study illustrates the initial experience with ixekizumab in real-world clinical practice confirming its usefulness and safety in the management of plaque psoriasis patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2018. PMID: 30317679. doi:10.1111/jdv.15288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。